# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant ⊠		Registrant ⊠	Filed by a Party other than the Registrant $\Box$	
Chec	k the ap	propriate box:		
	Prelii	minary Proxy Statement		
	Conf	fidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))		
	Defin	nitive Proxy Statement		
$\boxtimes$	Defin	nitive Additional Materials		
		iting Material Under Rule 14a-12		
			G1 Therapeutics, Inc. (Name of Registrant as Specified In Its Charter)	
			(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	
Paym	ent of I	Filing Fee (Check the	appropriate box):	
$\times$	No fe	fee required.		
	Fee c	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.		
	1)	Title of each class of	of securities to which transaction applies:	
	2)	Aggregate number	of securities to which transaction applies:	
	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):		
	4)	Proposed maximum aggregate value of transaction:		
	5)	Total fee paid:		
	Fee p	paid previously with preliminary materials.		
			ne fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was ne previous filing by registration statement number, or the Form or Schedule and the date of its filing:	
	1)	Amount previously	paid:	
	2)	Form, Schedule or	Registration Statement No:	
	3)	Filing party:		
	4)	Date Filed:		
		-		









000004

Սիիբերժաբգորդրիվովից|ՍՍիիգի**եգիյիմի**յր|Սիեգնգահնես

MR A SAMPLE DESIGNATION (IF ANY)

ADD 1 ADD 2

Online

C 1234567890



Go to www.envisionreports.com/GTHX or scan the QR code - login details are located in the shaded bar below.



Votes submitted electronically must be received by 11:59 pm (ET) on June 10, 2020

### **Stockholder Meeting Notice**

(1234 5678 9012 345)

### Important Notice Regarding the Availability of Proxy Materials for the G1 Therapeutics, Inc. Stockholder Meeting to be Held on June 11, 2020

Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders' meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Form 10-K, Notice and Proxy Statement for the year ended December 31, 2019, are available at:

# www.envisionreports.com/GTHX



### Easy Online Access – View your proxy materials and vote.

- Go to www.envisionreports.com/GTHX.
- Click on Cast Your Vote or Request Materials. Step 2:
- Follow the instructions on the screen to log in.
- Make your selections as instructed on each screen for your delivery preferences.
- Step 5: Vote your shares.

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.



Obtaining a Copy of the Proxy Materials - If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 28, 2020 to facilitate timely delivery.







03915C

### **Stockholder Meeting Notice**

G1 Therapeutics, Inc.'s Annual Meeting of Stockholders will be held on June 11, 2020 at G1 Therapeutics, Inc., 700 Park Offices Drive, Research Triangle Park, NC 27709, at 8:00 a.m. Eastern Time.

Proposals to be voted on at the meeting are listed below along with the Board of Directors' recommendations.

The Board of Directors recommends a vote FOR the election of all nominees listed, FOR Proposals 2 and 3:

The election of three Class III Directors.

Nominees: Garry A. Nicholson Mark A. Velleca, M.D., Ph.D. Glenn P. Muir

- 2. An advisory (non-binding) vote to approve executive compensation
- 3. The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020.

PLEASE NOTE - YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.



#### Here's how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current meeting materials.

**PLEASE NOTE:** You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

- Internet Go to www.envisionreports.com/GTHX. Click Cast Your Vote or Request Materials.
- Phone Call us free of charge at 1-866-641-4276.
- Email Send an email to investorvote@computershare.com with "Proxy Materials G1 Therapeutics, Inc." in the subject line.
   Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 28, 2020.